NCT02415621 2025-12-04
Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
Clinical Trials
12 trialsNCT03098836 2025-09-12
PANTHER
Duke University
Phase 2 Completed
NCT06652607 2025-03-12
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT04887506 2024-01-16
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics
Phase 3 Completed
NCT06193993 2024-01-08
Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients
National University Hospital, Singapore
Phase 1 Active not recruiting
NCT05422911 2022-06-21
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
James J. Peters Veterans Affairs Medical Center
Phase 2 Not yet recruiting
NCT01842321 2021-02-23
AMA
UNICANCER
Phase 2 Completed
NCT01940276 2020-12-09
Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer
Duke University
Phase 2 Completed
NCT02364531 2019-12-06
COSMiC
Janssen Inc.
Completed
NCT01381874 2019-04-11
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Janssen Research & Development, LLC
Phase 2 Completed
NCT01393730 2018-03-15
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed